Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BNB PLUS CORP.APDN · Entity 8621 | Director | May 17, 2019 | May 21, 2019 |
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director | March 25, 2019 | March 25, 2019 |
| Neurotrope, Inc.NTRP · Entity 144906 | Director · 10% owner | December 01, 2020 | December 03, 2020 |
| Polaryx Therapeutics, Inc.PLYX · Entity 6769 | Director | January 29, 2026 | January 29, 2026 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | President | January 23, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BNB PLUS CORP.
Report date May 17, 2019 · Filed May 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2029-05-16 | Direct | 175,435 |
Reported balance
After 2019-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-17 · Grant · Acquired 175,435 · Balance 175,435 F1: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date.
BioRestorative Therapies, Inc.
Report date March 25, 2019 · Filed March 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2025-04-06 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2025-04-06 | Direct | 15,000 |
Reported balance
After 2019-03-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-25 · Grant · Acquired 15,000 · Balance 15,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2025-09-04 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2025-09-04 | Direct | 20,000 |
Reported balance
After 2019-03-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-03-25 · Grant · Acquired 20,000 · Balance 20,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-03-25 · Disposition to issuer · Disposed 46,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3: The option is exercisable to the extent of 15,334 shares on June 10, 2016 and 15,333 shares on each of June 10, 2017 and June 10, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-06-10 | Direct | 46,000 |
Reported balance
After 2019-03-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-25 · Grant · Acquired 46,000 · Balance 46,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3: The option is exercisable to the extent of 15,334 shares on June 10, 2016 and 15,333 shares on each of June 10, 2017 and June 10, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2027-06-23 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-25 · Disposition to issuer · Disposed 100,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2027-06-23 | Direct | 100,000 |
Reported balance
After 2019-03-25 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-25 · Grant · Acquired 100,000 · Balance 100,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-03-25 · Disposition to issuer · Disposed 75,000 · Balance 0 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2028-10-29 | Direct | 75,000 |
Reported balance
After 2019-03-25 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-03-25 · Grant · Acquired 75,000 · Balance 75,000 F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 42,917 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 42,917 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2020-05-08 | Direct | 2,500 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2,500 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2020-11-12 | Direct | 6,250 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,250 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2022-03-01 | Direct | 26,667 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 26,667 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018.
F2: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018.
F3: The option is exercisable to the extent of 15,334 shares on June 10, 2016 and 15,333 shares on each of June 10, 2017 and June 10, 2018.
F4: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019.
F5: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020.
F6: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.55 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 157,918 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 79,097 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 130,680 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Polaryx Therapeutics, Inc.
Report date January 29, 2026 · Filed January 29, 2026
This filing explicitly reported no securities owned.
Quince Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2036-01-23 | Direct | 200,000 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 23, 2026 20:07 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000912282-26-000120 · form4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2036-01-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:46 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantWarrants · Derivative | 7,548 | $0.13 Strike: $1.20 | $943.50 |
DisclosureSEC source: 0000912282-25-000696 · form4.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,548 Underlying: Common Shares · 7,548 shares Expires 2030-06-18 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:46 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantCommon Shares | 7,548 | $1.20 | $9,057.60 |
DisclosureSEC source: 0000912282-25-000696 · form4.xml · nonDerivative · entry 1 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,009 Read SEC document |
| January 28, 2025 Filed Feb 11, 2025 17:43 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001415889-25-003615 · form4-02112025_100214.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 17:51 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 48,387 | $0.65 | $31,451.55 |
DisclosureSEC source: 0001415889-24-022054 · form4-08222024_090813.xml · nonDerivative · entry 1 Ryan Charles S. · CIK 0001624830 · PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,461 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.62 to $0.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 18:02 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001415889-24-002380 · form4-02022024_110255.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 17:43 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 545,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001209191-23-048483 · doc4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,000 Underlying: Common Stock · 545,000 shares Expires 2033-08-31 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest one year after the date of the grant of September 1, 2023 and the remaining shares will vest in equal monthly installments over the following three years thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001104659-20-132153 · tm2037705d6_4.xml · derivative · entry 5 Ryan Charles S. · CIK 0001624830 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 130,680 | Not disclosed Strike: $0.78 | Not disclosed |
DisclosureSEC source: 0001104659-20-132153 · tm2037705d6_4.xml · derivative · entry 4 Ryan Charles S. · CIK 0001624830 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,680 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001104659-20-132153 · tm2037705d6_4.xml · derivative · entry 3 Ryan Charles S. · CIK 0001624830 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 79,097 | Not disclosed Strike: $4.37 | Not disclosed |
DisclosureSEC source: 0001104659-20-132153 · tm2037705d6_4.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,097 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:41 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 157,918 | Not disclosed Strike: $7.55 | Not disclosed |
DisclosureSEC source: 0001104659-20-132153 · tm2037705d6_4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,918 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 17:09 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-20-130079 · tm2037145d6_4seq1.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). F2 · derivative.expiration_date: In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 130,680 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-19-073078 · tm1925244-1_form4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,680 Underlying: Common Stock · 130,680 shares Expires 2029-12-13 F1 · derivative.exercise_date: The stock options shall vest in equal daily installments over a two-year period beginning on the date of grant. Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:09 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 175,435 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001144204-19-027507 · tv522085_4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,435 Underlying: Common Stock · 175,435 shares Expires 2029-05-16 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 75,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 14 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 75,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 13 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 100,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 12 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-06-23 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 100,000 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 11 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-06-23 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 46,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 9 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2026-06-10 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 15,334 shares on June 10, 2016 and 15,333 shares on each of June 10, 2017 and June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 46,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 8 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,000 shares Expires 2026-06-10 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 15,334 shares on June 10, 2016 and 15,333 shares on each of June 10, 2017 and June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 20,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 7 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-09-04 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 20,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 6 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-09-04 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 15,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 3 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-04-06 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 15,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007601 · doc1.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-04-06 F6 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002682 · v511522_4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 17:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 79,097 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001144204-18-064951 · tv509225_4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,097 Underlying: Common Stock · 79,097 shares Expires 2028-12-14 F1 · derivative.exercise_date: The stock options shall vest in equal daily installments over a three-year period beginning on the date of grant. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 20:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004863 · doc1.xml · derivative · entry 9 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F5 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| October 17, 2018 Filed Oct 17, 2018 18:15 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 12,778 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0001144204-18-054172 · tv504852_4.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,778 Underlying: Common Stock · 12,778 shares Expires 2023-10-17 F1 · kind: The two reported transactions involve an amendment of an outstanding option to extend the expiration date of such option from October 17, 2018 to October 17, 2023, resulting in the deemed cancelation of the "old" option and the grant of a replacement option. The option was originally granted on October 17, 2013 and provided for immediate vesting upon date of grant. F1 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option to extend the expiration date of such option from October 17, 2018 to October 17, 2023, resulting in the deemed cancelation of the "old" option and the grant of a replacement option. The option was originally granted on October 17, 2013 and provided for immediate vesting upon date of grant. Read SEC document |
| October 17, 2018 Filed Oct 17, 2018 18:15 UTC | BNB PLUS CORP. APDN · Entity 8621 | Disposition to issuerStock Option (right to buy) · Derivative | 12,778 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0001144204-18-054172 · tv504852_4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,778 shares Expires 2018-10-17 F1 · kind: The two reported transactions involve an amendment of an outstanding option to extend the expiration date of such option from October 17, 2018 to October 17, 2023, resulting in the deemed cancelation of the "old" option and the grant of a replacement option. The option was originally granted on October 17, 2013 and provided for immediate vesting upon date of grant. F1 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option to extend the expiration date of such option from October 17, 2018 to October 17, 2023, resulting in the deemed cancelation of the "old" option and the grant of a replacement option. The option was originally granted on October 17, 2013 and provided for immediate vesting upon date of grant. F1 · derivative.expiration_date: The two reported transactions involve an amendment of an outstanding option to extend the expiration date of such option from October 17, 2018 to October 17, 2023, resulting in the deemed cancelation of the "old" option and the grant of a replacement option. The option was originally granted on October 17, 2013 and provided for immediate vesting upon date of grant. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:05 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 7,204 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-015576 · tv488775_form4.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,204 Underlying: Common Stock · 7,204 shares Expires 2023-03-14 F2 · derivative.exercise_date: These options vest immediately upon date of grant. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:05 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 63,919 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-015576 · tv488775_form4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,919 Underlying: Common Stock · 63,919 shares Expires 2028-03-14 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 17:34 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 157,918 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001144204-17-064174 · tv481442_form4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,918 Underlying: Common Stock · 157,918 shares Expires 2027-12-14 F1 · security: These securities were issued in connection with the Reporting Person's appointment as a director to the Issuer's board of directors. F2 · derivative.exercise_date: Half of the stock options shall vest upon grant, and the remaining stock options shall vest daily over the following four-year period. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 23:04 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantCommon Stock | 14,205 | $1.76 | $25,000.80 |
DisclosureSEC source: 0001571049-17-006372 · t1700414e-ryan0628.xml · nonDerivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,205 Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 21:06 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-17-026108 · doc1.xml · derivative · entry 8 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-06-23 F4 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 26,667 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010429 · doc1.xml · derivative · entry 7 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 26,667 shares Expires 2022-03-01 F1 · price: In exchange for accrued director fees. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 17:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 26,667 | $3.00 | $80,001.00 |
DisclosureSEC source: 0001140361-17-010429 · doc1.xml · nonDerivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,917 F1 · price: In exchange for accrued director fees. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 18:58 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 20,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007883 · doc1.xml · derivative · entry 7 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-09-04 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 18:58 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 20,000 | Not disclosed Strike: $7.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007883 · doc1.xml · derivative · entry 6 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-09-04 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 18:58 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 15,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007883 · doc1.xml · derivative · entry 3 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-04-06 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 18:58 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 15,000 | Not disclosed Strike: $8.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007883 · doc1.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-04-06 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:07 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 44,787 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001571049-16-020816 · t1600811e-ryan1220.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,787 Underlying: Common Stock · 44,787 shares Expires 2026-12-19 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.